Biofrontera Inc. (BFRI)
| Market Cap | 11.46M +84.7% |
| Revenue (ttm) | 43.20M +13.7% |
| Net Income | -11.09M |
| EPS | -1.02 |
| Shares Out | 12.01M |
| PE Ratio | n/a |
| Forward PE | 5.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,215 |
| Open | 0.8990 |
| Previous Close | 0.8860 |
| Day's Range | 0.8733 - 0.9600 |
| 52-Week Range | 0.5526 - 1.1900 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 5.88 (+516.22%) |
| Earnings Date | May 14, 2026 |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Financial Performance
In 2025, Biofrontera's revenue was $41.71 million, an increase of 11.75% compared to the previous year's $37.32 million. Losses were -$10.54 million, -40.67% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for BFRI stock is "Strong Buy." The 12-month stock price target is $5.88, which is an increase of 516.22% from the latest price.
News
Biofrontera Transcript: Lytham Partners Spring 2026 Investor Conference
The company highlighted strong year-over-year revenue growth, improved gross margins, and a robust dermatology product pipeline. Key regulatory submissions are planned for 2026, targeting expanded indications and market share, with financials showing a path to break-even.
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of p...
Biofrontera downgraded to Speculative Buy from Buy at Benchmark
Benchmark analyst Bruce Jackson downgraded Biofrontera (BFRI) to Speculative Buy from Buy with a $3 price target after the company reported in line Q1 results and reiterated its plans to…
Biofrontera Earnings Call Transcript: Q1 2026
Q1 2026 saw 17% revenue growth, gross margin expansion to 80%, and near-zero cash burn, reflecting the benefits of a new cost structure and strong commercial execution. Clinical pipeline advanced with FDA sNDA acceptance for SBCC and positive data in AK and acne.
Biofrontera Earnings release: Q1 2026
Biofrontera released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Biofrontera Quarterly report: Q1 2026
Biofrontera has published its Q1 2026 quarterly earnings report on May 14, 2026.
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo...
Biofrontera Proxy statement: Proxy filing
Biofrontera filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Biofrontera Earnings Call Transcript: Q4 2025
Record 2025 revenues and Q4 profitability were driven by strong Ameluz sales, a transformative asset acquisition, and a new cost structure. Clinical pipeline advances and expanded IP position set the stage for margin expansion and growth in 2026.
Biofrontera Annual report: Q4 2025
Biofrontera has published its Q4 2025 annual report on March 19, 2026.
Biofrontera Earnings release: Q4 2025
Biofrontera released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera (BFRI) Inc., stated: “2025 was a transformational year for Biofrontera. We delivered record annual and fourth quarter revenues, cl...
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company special...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of...
Biofrontera reports Phase 2b results of Ameluz PDT in acne vulgaris
Biofrontera (BFRI) announced results of its Phase 2b clinical trial evaluating Ameluz topical gel, 10% PDT for the treatment of moderate to severe acne vulgaris. The multicenter, randomized, double-bl...
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle
Biofrontera reports USPTO decision on Sun Pharma’s challenged claims
Biofrontera (BFRI) announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U....
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), tod...
Biofrontera announces database lock of Phase 1 PK study of Ameluz
Biofrontera (BFRI) announced that the database of its Phase 1 Pharmacokinetics, PK, study evaluating Ameluz topical gel for the treatment of mild to moderate actinic keratoses, AKs, on neck, trunk…
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera announces FDA acceptance of sNDA for Ameluz PDT
Biofrontera (BFRI) announced that the U.S. Food and Drug Administration has completed its filing review and accepted filing of the Company’s supplemental New Drug Application for Ameluz topical gel us...
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of ...
Biofrontera announces positive Phase 3 results for Ameluz PDT
Biofrontera (BFRI) announced positive and statistically significant top-line results from its Phase 3 clinical trial evaluating Ameluz PDT with the red-light LED, or RhodoLED, platform for the treatme...
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
WOBURN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Biofrontera Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Biofrontera and LSL Pharma Group presented at the Lytham Partners 2026 Investor Healthcare Summit, outlining robust revenue growth, margin expansion, and strategic initiatives. Both companies are leveraging acquisitions, product innovation, and market expansion to drive future performance.